共 50 条
- [21] Novel controlled-release Lemna-derived IFN-α2b (Locteron):: Pharmacokinetics, pharmacodynamics, and tolerability in a phase I clinical trialJOURNAL OF INTERFERON AND CYTOKINE RESEARCH, 2008, 28 (02): : 113 - 122De Leede, Leo G. J.Humphries, John E.Bechet, Anne C.Van Hoogdalem, Ewoud J.Verrijk, RuudSpencer, David G.
- [22] Safety, tolerability, pharmacokinetics(PK) and pharmacodynamics(PD) of HSK31858,a novel DPP-1 inhibitor in healthy volunteers:a phase I clinical trialEUROPEAN RESPIRATORY JOURNAL, 2023, 62Hou, JieGuan, Wei JieLi, Fang QiongZeng, Wei FangLiu, Han Mo
- [23] Characterization of pharmacokinetics, pharmacodynamics, tolerability and clinical activity in phase I studies of the novel allosteric tyrosine kinase 2 (TYK2) inhibitor NDI-034858JOURNAL OF INVESTIGATIVE DERMATOLOGY, 2022, 142 (08) : S54 - S54Gangolli, E. A.Carreiro, S.McElwee, J. J.Dave, N.Lombardi, A.Hanna, J.Hosagrahara, V.Srivastava, B.
- [24] Clinical tolerability and pharmacokinetics of Erigerontis hydroxybenzene injection: Results of a randomized phase I study in healthy Chinese volunteersPHYTOMEDICINE, 2015, 22 (02) : 319 - 325Ju, Wen-ZhengZhao, YangLiu, FangWu, TingZhang, JunLiu, Shi-JiaZhou, LingDai, Guo-LiangXiong, Ning-NingFang, Zhu-Yuan
- [25] Pharmacokinetics, pharmacodynamics, and tolerability of BCD-017, a novel pegylated filgrastim: Results of open-label controlled phase I study with dose escalation in healthy volunteers.JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (15)Nikitin, Kirill D.Fitilev, Sergei B.Chernovskaya, Tatiana V.Rudenko, Elena G.Vozzhaev, Alexander V.Titarova, Yulia Y.Yakushev, Vadim A.Ivanov, Roman A.
- [26] Safety, Tolerability, Pharmacokinetics (pk) And Pharmacodynamics (pd) Of Gsk2339345-Novel Sodium Channel Blocker. Results From Two Phase I Studies In Healthy VolunteersAMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 2014, 189Marks-Konczalik, J.Murdoch, R. D.Kelly, K. L.Cheesbrough, A.Siederer, S. K.Singh, D.Smith, J. A.
- [27] Phase I pharmacokinetics and pharmacodynamics of GDC-0152, a novel IAP protein antagonist, administered to patients with locally advanced or metastatic malignanciesEJC SUPPLEMENTS, 2010, 8 (07): : 125 - 125Fairbrother, W.LoRusso, P.Wagner, A.Budha, N.Darbonne, W.Shin, Y.Wong, H.Chan, I.Ware, J.Eckhardt, S. G.
- [28] Efficacy and Safety of Clifutinib, a Novel, Highly Selective, Oral FLT3 Inhibitor, in Patients with FLT3-Mutated Relapsed or Refractory Acute Myeloid Leukemia:Updated Results from a Phase I StudyBLOOD, 2023, 142Jin, JieWang, HuafengYu, Wen-JuanGe, ZhengWei, XudongLi, YuhuaJiang, ZhongxingLi, YiqingDu, XinYang, LinhuaLin, LieWang, JishiYao, YazhouHu, XiaopingLan, JianpingDeng, XiuzhiChen, TongFeng, XianqiLi, DengjuHou, MingFu, RongHuang, SiyongWang, JingboDu, XinYang, HuiYang, HaipingJiang, YingzhiWang, ZhijieLi, DengLiu, BingKang, NingZhuang, YuleiZhang, Yingjun
- [29] A Randomized Placebo-Controlled Phase 1 Trial in Healthy Volunteers Investigating the Safety, Pharmacokinetics and Pharmacodynamics of a Novel FLT3/IRAK4 Inhibitor, Lomonitinib (ZE46-0134)BLOOD, 2024, 144 : 1396 - 1397Byrd, John C.Burd, AmyLedwith, BrianPickersgill, FraserDokukina, KateKarapetian, RubenJohnstone, Megan E.Hertlein, Erin K.Elgamal, Ola A.Pushechnikov, AlexeiSavchuk, NikolayDukes, Iain
- [30] EVALUATION OF THE SINGLE DOSE PHARMACOKINETICS, PHARMACODYNAMICS, AND SAFETY OF GS-3583, A FLT3 AGONIST FC FUSION PROTEIN, IN A PHASE 1 STUDY IN HEALTHY VOLUNTEERS.CLINICAL PHARMACOLOGY & THERAPEUTICS, 2022, 111 : S18 - S18Dauki, A.Rajakumaraswamy, N.Trowe, T.Singh, I.Vashishtha, A.Weng, W.Kuhne, M.Qin, A.Schwabe, C.Othman, A.